[Comrades! There must be some blood order in the field of hypertension!].
Melander
Arne
A
NEPI, Malmö och Stockholm. arne.melander@nepi.net
D000319:Adrenergic beta-Antagonists / Q000008:administration & dosage; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000191:economics; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers / Q000008:administration & dosage; D003362:Cost-Benefit Analysis; D004232:Diuretics; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D012307:Risk Factors; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D001581:Benzothiadiazines; D002121:Calcium Channel Blockers; D004232:Diuretics; D049993:Sodium Chloride Symporter Inhibitors